Trethera presenting at the 2018 San Diego Health Impact Forum
Trethera will be presenting at the 2018 San Diego Health Impact Forum on February 7th, 2018 held at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
Entries by admin
Trethera attending the 59th ASH Annual Meeting in Atlanta
November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.
Trethera at BioPharm America
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.
Trethera to attend RESI Boston 2017
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.
SOHO 2017 Annual Meeting
September 7, 2017 – Trethera will be attending the Society of Hematologic Oncology’s Annual Meeting, September 13-15, 2017, in Houston, Texas. For more information on Trethera’s attendance, please contact info@trethera.com
Biocom’s Global Life Science Partnering Conference, 2017
1-2 March 2017 La Jolla, CA
Biocom’s Global Life Science Partnering Conference, 2016
February 24 – 25, 2016
BIO International Convention, 2016
6-9 June 2016 San Francisco, CA
ASCO Annual Meeting, 2016
3-7 June 2016 Chicago, IL
Structure-Guided Development of Deoxycytidine Kinase Inhibitors with Nanomolar Affinity and Improved Metabolic Stability
Abstract: Recently, we have shown that small molecule dCK inhibitors in combination with pharmacological perturbations of de novo dNTP biosynthetic pathways could eliminate acute lymphoblastic leukemia cells in animal models. However, our previous lead compound had a short half-life in vivo. Therefore, we set out to develop dCK inhibitors with favorable pharmacokinetic properties. We delineated […]